Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models
- 30 October 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (771) , eadi9004
Abstract
In anticancer research, tumor growth measured in mouse models is important for assessing treatment efficacy for a treatment to progress to human clinical trials. Statistical analysis of time-to-event tumor volume data is complex because of heterogeneity in response and welfare-related data loss. Traditional statistical methods of testing the mean difference between groups are not robust because they assume common responses across a population. Heterogeneity in response is also seen in the clinic, and consequently, the assessment of the treatment considers the diversity through classification of the individual’s response using the RECIST (Response Evaluation Criteria in Solid Tumors). To provide a comparable and translatable assessment of in vivo tumor response, we developed a statistical method called INSPECT (IN vivo reSPonsE Classification of Tumors) for analyzing heterogeneous responses through Bayesian modeling. This method can classify individual tumor behaviors into the categories of nonresponder, modest responder, stable responder, and regressing responder. Using both published and simulated data, we show that INSPECT methodology is more accurate and sensitive than existing methods with respect to balancing false-negative and false-positive rates. A case study demonstrates the value of INSPECT in drug projects for supporting the translation of drug efficacy from the preclinical phase into clinical trials. We also provide a package, “INSPECTumours,” that launches a web interface to enable users to conduct the analysis and generate reports.Keywords
This publication has 21 references indexed in Scilit:
- A comparison of statistical methods for animal oncology studiesPharmaceutical Statistics, 2022
- Assessing the performance of different outcomes for tumor growth studies with animal modelsAnimal Models and Experimental Medicine, 2022
- Impact of a five-dimensional framework on R&D productivity at AstraZenecaNature Reviews Drug Discovery, 2018
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid TumorsJAMA Oncology, 2016
- US cancer institute to overhaul tumour cell linesNature, 2016
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseNature Medicine, 2015
- Intra-tumor heterogeneity of cancer cells and its implications for cancer treatmentActa Pharmacologica Sinica, 2015
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009